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ABSTRACT
Introduction Stroke is a leading cause of death and 
disability. The development of dementia after stroke is 
common. Vascular risk factors (VRF) which contribute 
to stroke risk can also contribute to cognitive decline, 
especially in vascular dementia (VaD). There is no 
established treatment for VaD, therefore strategies for 
prevention could have major health resource implications. 
This study was designed to assess whether patients with 
early cognitive decline after stroke/transient ischaemic 
attack (TIA) can be easily identified and whether  
target-driven VRF management can prevent progression to 
dementia.
Objectives The primary objective is to establish the 
feasibility of recruitment and retention of patients with 
early cognitive decline to a randomised controlled trial 
of enhanced VRF management. Secondary objectives 
include: (a) to determine the potential clinical benefit 
of the intervention; (b) to estimate the sample size for 
a future definitive multicentre randomised controlled 
trial; (c) to inform a future economic evaluation; (d) to 
explore the link between VRF control and the incidence 
of cognitive impairment on longitudinal follow-up in 
a UK population after stroke/TIA with current routine 
management.
Methods 100 patients with cognitive decline poststroke/
TIA will be recruited from stroke services at the Norfolk 
and Norwich University Hospital. After collection of 
baseline data, they will be randomised to intervention 
(3 monthly follow-up with enhanced management) or 
control (treatment as usual by the general practitioner). 
At 12 months outcomes (repeat cognitive testing, VRF 
assessment) will be assessed. A further 100 patients 
without cognitive decline will be recruited to a parallel 
observational group from the same site. At 12 months they 
will have repeat cognitive testing.
Ethics and dissemination Ethical approval has 
been granted in England. Dissemination is planned 
via publication in peer-reviewed medical journals and 
presentation at relevant conferences.
Trial registration number 42688361; Pre-results.
InTROduCTIOn
Background
Stroke is one of the leading causes of death 
and disability1 and current demographic 
trends suggest that the total numbers of 
people with a stroke will rise due to the 
ageing population.2 Cognitive decline after 
stroke poses a significant problem consid-
ering that up to 30% of patients may poten-
tially develop dementia as early as 3 months 
after their cerebrovascular event.3 Stroke may 
unmask previously unrecognised cognitive 
impairment,4 5 or may trigger new cognitive 
decline due to VaD, Alzheimer’s disease or 
mixed pathology.6 7 
The World Alzheimer Report emphasised 
the benefit of early diagnosis with future 
savings from delayed institutionalisation and 
care costs across the disease course.8 Similarly, 
the UK Government has identified the timely 
diagnosis of dementia in primary care as a 
priority.9 An effective strategy in preventing 
VaD could have major resource implications, 
with at least one in five dementia cases having 
a VaD element and dementia costing the UK 
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Protocol
Strengths and limitations of this study
 ► The protocol uses a validated cognitive screening 
test, which is sensitive and specific for the detection 
of mild cognitive impairment as well as dementia.
 ► Data will be collected on a range of vascular risk 
factors.
 ► The study is open-label, but repeat cognitive testing 
will be completed by a member of the research team 
who is blinded to allocation and baseline cognitive 
status.
 ► The chosen follow-up period of 12 months may limit 
our ability to detect changes in cognition.
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economy £23 billion per year.10 Most importantly, ‘how 
best to improve cognition after stroke’ was reported to be the 
highest priority research topic in a survey of patients with 
stroke.11 Identifying patients who have signs of early cogni-
tive decline after stroke or TIA could provide a window of 
opportunity for saving resources and improving patient 
outcomes if further cognitive decline could be prevented.6
It is reported that dementia is common after stroke 
and TIA.3 4 12 13 Reported rates range from 7.4% up to 
41.3% with the variance mostly dependent on the mix of 
the cohort (eg, rates are higher in secondary care cohorts 
and those with higher rates of recurrent stroke).14 Our 
previous work shows that the risk of developing cogni-
tive impairment appears to be greater in people with 
higher numbers of VRF4 and other work suggests that 
the presence of cardiovascular risk factors increases the 
risk of early cognitive decline progressing to dementia.15 
Improved control of VRF leading to enhanced secondary 
stroke prevention may therefore help to prevent further 
cognitive decline after stroke/TIA in high-risk patients 
with evidence of early cognitive impairment.
Rationale for the study
Observational evidence indicates that both VaD and 
Alzheimer’s dementia may have risk factors in common 
with stroke, namely VRF such as high blood pressure (BP) 
and diabetes.16 17 Despite this, whether intervening to 
control these risk factors can prevent dementia remains 
unclear.16 18 First, trials of antihypertensive therapy have 
been inconsistent. However, they may have been limited 
by high rates of treatment in placebo groups, high 
dropout rates and short follow-up.18 Of note, a large trial 
which recruited patients with stroke/TIA (PROGRESS) 
did demonstrate reduced cognitive decline, but not 
dementia, with treatment.16 18 Furthermore, meta-anal-
ysis of placebo-controlled trials suggests that antihyper-
tensive therapy reduces the risk of dementia.19 Second, 
two randomised controlled trials have assessed the use 
of statins and found no benefit on cognition despite 
reduction in cholesterol levels.20 Third, in the ADVANCE 
study intensive blood glucose control in type 2 diabetics 
successfully reduced microvascular complications, but 
did not reduce rates of dementia.18 Finally, whether anti-
coagulation for atrial fibrillation (AF) can prevent cogni-
tive decline is, at present, not addressed by the available 
evidence.16 17 In spite of this uncertainty there is evidence, 
as alluded to earlier, that recurrent stroke is an important 
factor in poststroke dementia.14 Given that treating VRF 
is beneficial for secondary stroke prevention, it therefore 
remains plausible that this could also have an impact on 
cognitive decline poststroke and further research is justi-
fied. Evidence to support this comes from a randomised 
controlled trial in Germany, which demonstrated a signif-
icant reduction in the need for long-term care in older 
adults following an intervention involving systematic 
identification and evidence-based treatment of cardio-
vascular risk factors.21 Although two trials similar to ours 
have investigated the use of an intervention targeted at 
controlling VRF for preventing cognitive decline after 
stroke and neither demonstrated a benefit of interven-
tion at 12 months,22 23 a key difference with our study is 
that we will be targeting patients who already have signs 
of cognitive impairment at baseline and therefore are at 
higher risk of further decline.
Routine cognitive testing using validated measures 
which are simple and quick, such as the Montreal Cogni-
tive Assessment (MoCA), which are shown to be sensitive 
and specific in detecting vascular-related cognition can 
identify those who are at risk of developing decline.24–26 
We believe therefore, that detection of early cognitive 
decline in stroke and TIA is feasible at the time of diag-
nosis in secondary care and we propose that enhanced 
(target driven) VRF control is clinically effective, cost-ef-
fective and safe.
The reported incidence of dementia poststroke is vari-
able, with the highest rates being over 40%.7 14 Reporting 
differences are strongly attributable to variation in the 
cohorts studied.14 There is also some evidence to suggest 
that cognitive decline after TIA or minor stroke (defined 
as National Institute of Health Stroke Scale <3) may be 
transient.27 However, there is a lack of data based on the 
current UK population. This study will therefore incor-
porate a parallel observational arm with a view to gener-
ating relevant epidemiological data in order to provide 
better insight regarding cognition after stroke/TIA in 
this patient population.
Study objectives
The primary objective of the study is to determine the 
feasibility of randomising patients who have signs of early 
cognitive decline, but no dementia, into routine risk 
factor management or enhanced risk factor management 
by their GP, and to assess adherence to the proposed 
intervention by enrolled participants.
The secondary objectives are as follows:
a. Determine the potential clinical benefit of enhanced 
control of VRF in preventing progression of 
cognitive decline and the development of dementia 
poststroke/TIA.
b. Assess indicative cost-effectiveness of this 
intervention.
c. Estimate the sample size for a future definitive 
multicentre randomised controlled trial.
d. Identify any adverse events due to the intervention, 
including rates of recurrent stroke/TIA.
e. Explore the incidence of cognitive impairment 
on longitudinal follow-up in a UK population 
after stroke/TIA with current routine risk factor 
management.
METhOdS And AnAlySIS
Study overview
This study is a single-centre, open-label parallel group 
study to determine the feasibility of conducting a 
randomised controlled trial in a National Health 
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Figure 1 Summary of the study design depicting the flow of participants through the study. Steps detailed include the 
identification and recruitment of participants, allocation and randomisation into the study arms based on Montreal Cognitive 
Assessment (MoCA) score, and the timing of intervention and follow-up visits. GP, general practitioner; TIA, transient ischaemic 
attack.
Service (NHS) setting on patients following stroke or TIA 
who have early cognitive decline. The aim is to target risk 
factors more intensively through enhanced monitoring 
and control of VRF compared with usual care. We wish to 
estimate the potential clinical impact and cost-effective-
ness of this intervention, and the sample size for a future 
multicentre definitive study in an NHS setting.
There is a parallel observational study arm for patients 
with no evidence of cognitive decline who will have their 
VRF and cognitive function assessed at follow-up. The 
objective of the parallel observational study is to better 
understand the link between VRF, their control and 
the development of cognitive decline after a cerebro-
vascular event. Combining the control arm of the feasi-
bility trial and observational cohort will provide further 
information on these links, including a realistic esti-
mate of the magnitude of effect of enhanced risk factor 
management in planning a future trial. A summary of 
the study design is provided in figure 1. Recruitment 
commenced in November 2015, was completed in July 
2017 and final follow-up data collection will be in July 
2018. The study has been registered on 16 April 2015: 
International Standard Randomised Controlled Trial 
Number 42688361.
Trial participants
All adult patients with confirmed stroke (first/recurrent) 
or TIA, identified within 8 weeks of diagnosis will be 
considered for the trial.
Inclusion criteria
 ► Participant is willing and able to give informed 
consent for participation.
 ► Male or female, aged 18 years or above.
 ► Diagnosed clinically and radiologically with stroke 
(infarct or haemorrhage) or TIA.
Exclusion criteria
The participant may not enter the trial if ANY of the 
following apply:
 ► Established dementia.
 ► Life expectancy <1 year.
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 ► Comorbidities that adversely affect their ability to 
accurately complete the MoCA.
 ► Patients who do not wish to know about their 
cognition.
Identification of participants
Eligible patients will be given a detailed Patient Informa-
tion Sheet (PIS) and Consent Form for consideration. 
After 24 hours the study team will contact the patient 
again and those who agree to participate will provide 
written informed consent and undergo a simple and vali-
dated cognitive screening test (MoCA), unless this has 
already been carried out by the clinical team as part of 
their routine care, whereupon that score can be used 
for study purposes. If a MoCA has been administered 
by the TIA clinic team the patient will be given a PIS 
in clinic and be followed up by phone to discuss entry 
into the study. Patients who have previously attended 
stroke services may be screened retrospectively from the 
Capture TIA/Stroke hospital database and followed up 
by phone. Those who have a MoCA score ≥26 and who 
verbally consent to be contacted about the study are 
sent a study summary sheet, a study invitation letter and 
consent form. If they wish to participate, the completed 
consent form will be returned and countersigned by 
a delegated member of the study team. Those who do 
not have a MoCA score following their stroke or TIA 
are invited for an appointment to give consent to take 
part in the study and carry out the MoCA. The patient 
will be enrolled into the appropriate arm of the study 
depending on the MoCA score.
Assessing capacity and obtaining informed consent
The participant must personally sign and date the latest 
approved version of the Informed Consent Form. This 
will then be countersigned by a delegated member of the 
research team before any trial-specific procedures are 
performed. Written and verbal versions of the PIS will 
be presented to the participants detailing the trial ratio-
nale; participant involvement and responsibilities; the 
implications and constraints of the protocol; safeguards 
and processing of blood tests. It will be clearly stated that 
the participant is free to withdraw from the trial at any 
time for any reason without prejudice to future care, and 
with no obligation to give the reason for withdrawal. The 
member of the research team who takes consent will be 
delegated to do so, be familiar with the study and be suit-
ably qualified to obtain consent for research purposes. A 
copy of the signed informed consent will be given to the 
participant, and another will be stored at the Norfolk and 
Norwich University Hospital Clinical Research Trials Unit 
(CRTU). The original signed form will be retained in the 
patient’s medical records.
Allocation into study arms
Allocation is based on the patient’s MoCA score, inter-
preted in the following manner:
 ► Score ≥26 indicates normal cognition, with this score 
being chosen to maximise the sensitivity of the test for 
detecting early cognitive decline.
 ► Score 20–25 suggests early cognitive decline.24 25
 ► Score ≤17 suggests possibility of dementia.28
normal cognition (MoCA score ≥26)
Patients with normal cognition will be informed of their 
result and will continue to receive usual care by their 
clinicians. They will be asked to confirm their willing-
ness to continue to participate in the observational study 
(group O) and will be followed up at 12 months.
Intermediate stage (MoCA score 20–25)
Patients will be informed of their result and asked to 
confirm their willingness to continue to participate in 
the feasibility trial. They will be randomised into one of 
two groups: control arm (group C) or intervention arm 
(group I). Randomisation will be based on computer-gen-
erated blocked randomisation managed by the Norwich 
CRTU.
Patients in group C will receive usual care by their clini-
cians and will be followed up at 12 months.
Patients in group I will undergo enhanced VRF manage-
ment through assessment by the study team at 3, 6 and 9 
months. Specific aims will be set for each modifiable risk 
factor and the GP will be informed about these targets 
and the results of each visit.
Greater degree of cognitive decline (MoCA score <20)
In view of the greater extent of cognitive impairment 
continued participation in the study is not suitable for 
these patients. They will be referred to specialist services 
where relevant, and their GP will be informed.
Interventions to be measured
Blood pressure
Existing evidence demonstrates that lowering of BP 
consistently and continuously reduces cardiovascular 
risk. This is supported by the Royal College of Physicians 
(RCP) guidelines’ aim for BP <140/90 mm Hg, with an 
ideal target BP <130/80 mm Hg for secondary preven-
tion.29 The effect of intervention on BP reduction using 
24-hour BP measurement at the beginning and end of 
the study will be examined. This will be recorded using a 
SpaceLabs 90 207 monitor programmed to measure BP at 
20 min intervals during the daytime (07:00–22:00 hours) 
and hourly overnight (22:00–07:00 hours).
Plasma lipids
The link between total cholesterol and dementia is 
controversial, but from a cardiovascular risk factor point 
of view lowering cholesterol by using statins improves 
stroke secondary prevention. Although poststroke 
dementia can be of VaD type, Alzheimer’s dementia or 
mixed pathology, lowering cholesterol should contribute 
to a reduced risk of poststroke dementia where the mech-
anism is one of VaD. Therefore, the cholesterol aim has 
been chosen as one of the ‘treat-to-target’ interventions. 
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The total cholesterol aim will be <4.0 mmol/L, which is 
in line with the RCP guidelines which were current at the 
trial inception.29
Atrial fibrillation
It has been shown that people with stroke and AF are more 
likely to be subsequently diagnosed with dementia.3 5 An 
intervention rate aim of 60–80 beats per minute has been 
chosen for patients with AF; those on warfarin will aim 
for an international normalised ratio (INR) between 
2.5 and 3 to maintain levels in the therapeutic window. 
There are no specific drug monitoring targets for other 
anticoagulants.
Ten minutes of continuous beat-to-beat BP measure-
ment will be carried out at baseline and the final follow-up 
using a Finometer device. These data can be used to assess 
heart rate variability as well as BP variability.
Blood glucose
Diabetes mellitus is associated with both microvascular 
and macrovascular disease, and hence carotid artery 
disease which is a preventable risk factor for stroke. It 
has been well documented that poor glucose control 
(assessed using haemoglobin A1c (HbA1c)) predicts 
stroke risk.30 Therefore, good diabetes control may 
prevent further cardiovascular risk and be associated with 
added benefit to future cognitive status. The aim is for 
HbA1c of 48–53 mmol/mol (or 6.5%–7%).
The patient’s GP will be informed by letter of the results 
that have been recorded during the research study. All 
patients will receive standard lifestyle advice relating to 
diet and weight, smoking and alcohol consumption.
Ordering of assessments
The following assessments will be carried out on all partic-
ipants at baseline (table 1):
 ► Eligibility assessment and informed consent;
 ► MoCA;
 ► Demographics, including age, gender, body mass 
index, smoking status, alcohol consumption and exer-
cise habits;
 ► Assessment of past medical history, including VRF;
 ► Record concomitant medications.
In addition, participants in groups C and I will complete 
at baseline:
 ► EQ5D (a generic health-related quality of life ques-
tionnaire), DEMQOL (Dementia Quality of Life 
measure), GDS (Geriatric Depression Scale question-
naire), Bristol Activities of Daily Living questionnaire 
and Morisky Medication Adherence Score;
 ► Resource use questionnaires;
 ► BP variability measures including 10 min of contin-
uous beat-to-beat BP recording and 24-hour BP 
monitoring;
 ► Pulse wave velocity (PWV) measurements (which 
reflect arterial stiffness).
Participants in group I will be seen at 3, 6 and 9 months 
at which time they will have assessment of their VRF and 
data collection for adverse events, including recurrent 
stroke/TIA.
All participants will be followed up at 12 months at 
which time they will have:
 ► MoCA;
 ► Assessment of VRF;
 ► Recording of concomitant medications;
 ► Data collection for adverse events, including recur-
rent stroke/TIA.
In addition, participants in group C and I will complete 
at 12 months:
 ► EQ5D, DEMQOL, GDS, Bristol Activities of Daily 
Living questionnaire and Morisky Medication Adher-
ence Score;
 ► Resource use questionnaires;
 ► BP variability measures;
 ► PWV measurements.
Outcome measurements
Primary outcome measure
Recruitment and retention rates at 12 months from the 
screening and study management logs.
Secondary outcome measures
a. Difference in mean change in MoCA score between 
groups C and I at 12 months;
b. Proportions of participants in each group whose 
vascular risk factors are controlled at each time 
point;
c. Frequency of adverse events in each group;
d. Indicative incremental cost per MoCA point and 
quality-adjusted life-year (QALY) gained by the 
intervention;
e. Mean change in MoCA score in group O related 
to number of VRF and proportion of participants 
whose VRF are controlled at baseline and outcome.
Sample size calculation
As this is a feasibility study a formal sample size calculation 
has not been performed. The duration and sample size of 
the study are based on the estimated prevalence rate of 
cognitive impairment at diagnosis (around 30%),4 inci-
dence of dementia after the event (~30% in 3 months),3 
estimated screening and recruitment rates. The aim is to 
include a minimum of 100 patients in the feasibility study 
(50 per group) and another 100 patients in the observa-
tional study.
data analysis plan
Primary objective
 ► Proportion of participants with MoCA score 20–25 
who consent to join the trial.
 ► Adherence to follow-up, including rates of withdrawal 
and loss to follow-up.
 ► Number of risk factors that need to be targeted in 
these patients administering the client service receipt 
inventory (CSRI) and quality of life questionnaires. 
Originally designed for costing psychiatric interven-
tions, the CSRI31 has been used as the core resource 
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use measurement tool for a wide variety of interven-
tions. It requires adapting to fit each study question, 
therefore the feasibility study will allow testing and 
revising of the questionnaire in preparation for the 
full study.
Secondary objectives
 ► Rates of control of VRF at baseline and outcome in 
each group.
 ► Proportion of participants in group I achieving VRF 
targets at 3, 6 and 9 months for each risk factor.
 ► Difference in mean change in MoCA score between 
groups C and I. The between-group comparison 
will be based on a general linear model with group 
as a fixed effect and including any prognostic varia-
bles at baseline for which there is a between-group 
disparity. A 95% CI for the difference in means will be 
constructed to give an idea of the likely magnitude of 
benefit from the intervention.
 ► Indicative incremental cost per point gained in MoCA, 
DEMQOL and per QALY gained between groups 
C and I. Data will be analysed in terms of costs and 
effects for the two groups. We will analyse key drivers 
of costs and examine the potential of this intervention 
to be cost-effective.
 ► Change in MoCA score between baseline and 12 
months in group O participants, and in groups O and 
C combined.
 ► Difference in adverse event rates between groups.
 ► Difference in mean BP between groups C and I.
 ► Difference in BP (systolic and diastolic) variability 
between groups C and I.
 ► Difference in PWV between groups C and I.
Ethics and dissemination
Study oversight will be conducted through regular meet-
ings of a Trial Steering Committee and a separate Safety 
Committee, both of which will include independent 
representatives. If it is felt that the risk to participants 
is significant or unacceptable the Safety Committee can 
recommend to early termination of the trial.
Data will be collected and handled in line with sponsor 
and Norwich CRTU procedures and NHS Trust policies. 
Electronic data will be anonymised and all data will be 
kept under secure conditions. Professor Potter will act as 
data custodian.
Dissemination of the study results is planned via publi-
cation in peer-reviewed medical journals and presenta-
tion at relevant scientific conferences. Any reporting will 
adhere to the Consolidated Standards of Reporting Trials 
statement extension for pilot and feasibility trials. We do 
not intend to employ professional writers.
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